Atezolizumab and Bevacizumab in Curatively-Treated GI Cancers With Microscopic Residual Disease

Phase 3, open-label, single-arm trial of atezolizumab and bevacizumab in colon adenocarcinoma, rectal adenocarcinoma, gastric adenocarcinoma and 4 more, sponsored by Georgetown University. Primary endpoints: Rates of Signatera ctDNA positive Patient identification at 12 months, Rate of Enrollment at 12 months and 3 more. Started Mar 2023; status: active, not recruiting.